Bayer : Q3 due 8 November – Attractive growth driven by CropScience, FX
>Projecting strong growth in CropScience for FY 2022, less so for FY 2023 - For FY 2022 we raise our segment sales and EBITDA forecast by 6% and 21% respectively, on longer-than-expected elevated price levels in herbicides. We now forecast segment sales of € 24,617m (css € 24,589m) and adj. EBITDA of € 6,661m (css € 6,751m). This compares to an estimated € 6.4bn implied by segment guidance raised in Q2 2022, when looking for 13% organic sales growth (ODDO: 12.5%) and...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.